Status:
COMPLETED
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
Lead Sponsor:
Akebia Therapeutics
Collaborating Sponsors:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial will be conducted to demonstrate the efficacy and safety of vadadustat compared to darbepoetin alfa for the maintenance treatment of anemia in hemodialysis participants after conversion fro...
Detailed Description
This study consists of three periods: 1. Screening Period 2. Conversion and Maintenance Treatment Period 3. Safety Follow-up Period Individual participants will participate in total trial duration o...
Eligibility Criteria
Inclusion
- Receiving chronic, outpatient three times weekly (TIW) in-center hemodialysis for end-stage renal disease for at least 12 weeks prior to Screening
- Hemodialysis adequacy as indicated by single-pool Kt/Vurea ≥ 1.2 using the most recent historical measurement within 8 weeks prior to or during Screening
- Use of any approved erythropoiesis-stimulating agents (ESAs) for at least the 8 weeks prior to Screening Visit 2
- Two hemoglobin (Hb) values, at least 4 days apart, measured by the central laboratory during Screening within the following prespecified ranges:
- Hb values between 8.0 and 11.0 grams per deciliter (g/dL) (inclusive) in the United States;
- Hb values between 9.0 and 12.0 g/dL (inclusive) in Europe
- Serum ferritin ≥ 100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) ≥ 20% during Screening
- Folate and vitamin B12 measurements ≥ lower limit of normal during Screening
Exclusion
- Anemia due to a cause other than chronic kidney disease (e.g., sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia)
- Participants meeting cut-off of the following equivalent mean weekly doses calculated over 8 weeks prior to Screening Visit 2
- Methoxy polyethylene glycol-epoetin beta \> 50 micrograms (µg)/week;
- Darbepoetin alfa \> 100 µg/week;
- Epoetin analogues \> 23000 International Units (IU)/week
- Active bleeding or recent blood loss within 8 weeks prior to randomization
- Red blood cell transfusion within 8 weeks prior to randomization
- Current uncontrolled hypertension.
- Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure (HF) or New York Heart Association Class IV HF, or stroke within 12 weeks prior to or during Screening.
- Known hypersensitivity to vadadustat, darbepoetin alfa, or any of their excipients
Key Trial Info
Start Date :
May 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 22 2022
Estimated Enrollment :
319 Patients enrolled
Trial Details
Trial ID
NCT04313153
Start Date
May 27 2020
End Date
June 22 2022
Last Update
May 22 2025
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Chula Vista, California, United States, 91910
2
Research Site
Granada Hills, California, United States, 91344
3
Research Site
Los Angeles, California, United States, 90022
4
Research Site
Lynwood, California, United States, 90262